TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Engrail Therapeutics Stock

Engrail Therapeutics Stock

www.engrail.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $221MM

Engrail Therapeutics is a pharmaceutical company focused on developing precision-targeted therapies striving to transform the lives of patients suffering from severe and life-limiting neurological, neuropsychiatric, and neurodevelopmental disorders. The company is seeking to leverage scientific insights into molecular mechanisms and neurocircuitry with the goal of advancing the development of novel treatments aimed at addressing unmet medical needs. Engrail Therapeutics was founded by Stephen Cunningham and Vikram Sudarsan in 2019 and is headquartered in San Diego, CA.

Buy or sell Engrail Therapeutics stockLearn more about Engrail Therapeutics IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Engrail Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Engrail Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Engrail Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Engrail Therapeutics investors also invested in these private companies

Norwest Venture Partners
Eight Roads Ventures
Longwood Fund
F-Prime Capital
Ysios Capital
Red Tree Venture Capital
Pivotal Life Sciences
Forbion
Abrdn
RiverVest Venture Partners

Team

Management Team

Vikram Sudarsan Ph.D
President & Chief Executive Officer
Kimberly Vanover Ph.D
Chief Scientific Officer
Quentin McCubbin Ph.D
Chief Technical Officer
Eve Taylor Ph.D
Senior Vice President, Clinical Development
Bill Brubaker Ph.D
Senior Vice President, Nonclinical Development
Rex E. Bosen CPA
Acting Chief Financial Officer
Estibaliz Arce Ph.D
Vice President, Translational Science and Clinical Development
Camilla Gomiero
Vice President, Commercial Strategy and Business Development
Anil Vootkur PharmD
Vice President, Corporate Development

Board Members

Jasper Bos Ph.D
Forbion
Niall O'Donnell Ph.D
RiverVest Venture Partners
Stacie Weninger Ph.D
F-Prime Capital
Tiba Aynechi Ph.D
Norwest Venture Partners
Karoly Nikolich Ph.D
Pivotal bioVenture Partners
Heath Lukatch Ph.D
Red Tree Venture Capital
Peter Bisgaard
Pivotal Life Sciences

Frequently Asked Questions About Engrail Therapeutics’ Stock

plusminus
Can you buy Engrail Therapeutics’ stock?
Engrail Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Engrail Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Engrail Therapeutics’ stock?
Yes, you can sell stock of a private company like Engrail Therapeutics. Forge can help you sell your Engrail Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Engrail Therapeutics’ stock price?
Engrail Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Engrail Therapeutics’ private market stock price with Forge Data.
plusminus
What is Engrail Therapeutics’ stock ticker symbol?
Engrail Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Engrail Therapeutics in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Life Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$500MM

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Dyno Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$539.27MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

The Economic Times 03/19/2024
Engrail Therapeutics raises $157 million in funding from F-Prime Capital, others
To continue developing treatment for neurodevelopment disorders, Engrail Therapeutics raised $157 million in a series B round.
Yahoo Finance 07/18/2023
Engrail Therapeutics Initiates the ENCALM Phase 2 Clinical Trial of ENX-102 in Patients with Generalized Anxiety Disorder
Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, today announced initiation of a multi-center phase 2 clinical trial, the ENCALM Trial, to evaluate the efficacy and safety of ENX-102 in patients with generalized anxiety disorder (GAD).

Trending Companies

Frequently Asked Questions

Updated on: May 20, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.